AI-ECG for Left Ventricular Dysfunction

Yale New Haven Hospital, New Haven, CT
Left Ventricular DysfunctionAI-ECG - Device
All Sexes

Study Summary

This trial aims to test a smartphone tool to detect heart problems, like LVSD, in everyday life.

Eligible Conditions
  • Left Ventricular Systolic Dysfunction

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: During study visit approximately 50 minutes

During study visit approximately 50 minutes
Successful detection of asymptomatic LVSD by AI-ECG

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: AI-ECG · No Placebo Group · N/A

Experimental Group · 1 Intervention: AI-ECG · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: during study visit approximately 50 minutes

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,728 Previous Clinical Trials
20,525,556 Total Patients Enrolled
Rohan Khera, MD, MSPrincipal InvestigatorYale University

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are researchers currently accepting new participants for this experiment?

"Currently, this clinical trial is not seeking any more participants as evidenced by the information on; which was first posted on December 1st 2022 and last edited November 29th 2022. Despite that, there are 46 other research studies actively recruiting at this time." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.